Saturday, October 3, 2026

USD/EUR Bearish By 1% In The Last 10 Sessions

USD/EUR Bearish By 1% In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.95% for the last 10 sessions. At 22:13 EST on Tuesday, 20 June, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.609% up from its 52-week low and 12.622% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.43%, a negative 0.08%, and a positive 0.36%, respectively.

USD/EUR's highest amplitude of average volatility was 0.52% (last week), 0.31% (last month), and 0.36% (last quarter), respectively.

News about

  • Eur/usd consolidates around 1.0940 due to mixed responses about fed’s rate guidance. According to FXStreet on Monday, 19 June, "The EUR/USD pair is oscillating in a narrow range around 1.0940 in the late Asian session. "
  • Eur/usd: less gloomy outlook for the US economy relative to the euro area to weigh on the pair – danske bank. According to FXStreet on Monday, 19 June, "We think that as long as sticky inflation remains a concern globally, we would expect the EUR/USD to remain soft.", "We still find the outlook for the US economy less gloomy relative to the Euro area, which should weigh on the EUR/USD in H2."
  • Eur/usd technical analysis: upward shift continues - 19 June 2023. According to DailyForex on Monday, 19 June, "According to the performance on the daily chart below, the upward shift in the EUR/USD currency pair continues. "
  • According to FXStreet on Monday, 19 June, "Hence, a sharp decline in the EUR/USD pair could help the US Dollar Index rise even if the US Dollar weakens against some of the other currencies in the basket."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com